- Home
- ETY vs FOLD Comparison
ETY vs FOLD Comparison
Compare ETY & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETY
- FOLD
- Stock Information
- Founded
- ETY 2006
- FOLD 2002
- Country
- ETY United States
- FOLD United States
- Employees
- ETY N/A
- FOLD N/A
- Industry
- ETY Finance Companies
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- ETY Finance
- FOLD Health Care
- Exchange
- ETY Nasdaq
- FOLD Nasdaq
- Market Cap
- ETY 2.4B
- FOLD 2.5B
- IPO Year
- ETY N/A
- FOLD 2007
- Fundamental
- Price
- ETY $15.43
- FOLD $9.49
- Analyst Decision
- ETY
- FOLD Buy
- Analyst Count
- ETY 0
- FOLD 7
- Target Price
- ETY N/A
- FOLD $30.29
- AVG Volume (30 Days)
- ETY 247.3K
- FOLD 4.9M
- Earning Date
- ETY 01-01-0001
- FOLD 11-04-2025
- Dividend Yield
- ETY 7.21%
- FOLD N/A
- EPS Growth
- ETY N/A
- FOLD N/A
- EPS
- ETY N/A
- FOLD N/A
- Revenue
- ETY N/A
- FOLD $598,704,000.00
- Revenue This Year
- ETY N/A
- FOLD $21.12
- Revenue Next Year
- ETY N/A
- FOLD $21.23
- P/E Ratio
- ETY N/A
- FOLD N/A
- Revenue Growth
- ETY N/A
- FOLD 21.28
- 52 Week Low
- ETY $10.59
- FOLD $5.51
- 52 Week High
- ETY $13.46
- FOLD $10.43
- Technical
- Relative Strength Index (RSI)
- ETY 39.67
- FOLD 67.88
- Support Level
- ETY $15.37
- FOLD $8.69
- Resistance Level
- ETY $15.87
- FOLD $9.64
- Average True Range (ATR)
- ETY 0.20
- FOLD 0.38
- MACD
- ETY -0.02
- FOLD 0.03
- Stochastic Oscillator
- ETY 28.23
- FOLD 85.29
About ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.